CN113993518A - 用于媒介传播疾病和病毒性疾病治疗或预防的全身异噁唑啉驱虫剂 - Google Patents

用于媒介传播疾病和病毒性疾病治疗或预防的全身异噁唑啉驱虫剂 Download PDF

Info

Publication number
CN113993518A
CN113993518A CN202080041597.8A CN202080041597A CN113993518A CN 113993518 A CN113993518 A CN 113993518A CN 202080041597 A CN202080041597 A CN 202080041597A CN 113993518 A CN113993518 A CN 113993518A
Authority
CN
China
Prior art keywords
isoxazoline
formulation
vector
doses
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080041597.8A
Other languages
English (en)
Chinese (zh)
Inventor
波巴克·罗伯特·扎米安
道格拉斯·迈克尔·阿克曼
克里斯托弗·斯蒂弗斯
肖恩·D·希科克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tassus Pharmaceutical Co ltd
Original Assignee
Tassus Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tassus Pharmaceutical Co ltd filed Critical Tassus Pharmaceutical Co ltd
Publication of CN113993518A publication Critical patent/CN113993518A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080041597.8A 2019-04-04 2020-04-03 用于媒介传播疾病和病毒性疾病治疗或预防的全身异噁唑啉驱虫剂 Pending CN113993518A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962829573P 2019-04-04 2019-04-04
US62/829,573 2019-04-04
PCT/IB2020/053229 WO2020202111A1 (en) 2019-04-04 2020-04-03 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis

Publications (1)

Publication Number Publication Date
CN113993518A true CN113993518A (zh) 2022-01-28

Family

ID=72667108

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080041597.8A Pending CN113993518A (zh) 2019-04-04 2020-04-03 用于媒介传播疾病和病毒性疾病治疗或预防的全身异噁唑啉驱虫剂

Country Status (11)

Country Link
US (2) US20220160682A1 (enExample)
EP (1) EP3946325A4 (enExample)
JP (1) JP2022527359A (enExample)
KR (1) KR20220054241A (enExample)
CN (1) CN113993518A (enExample)
AU (1) AU2020251960A1 (enExample)
BR (1) BR112021019931A2 (enExample)
CA (1) CA3136042A1 (enExample)
IL (1) IL286914A (enExample)
MX (1) MX2021012188A (enExample)
WO (1) WO2020202111A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118593485A (zh) * 2023-05-07 2024-09-06 M·法伯 异噁唑啉复合物及其组合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
KR20200111177A (ko) 2017-12-15 2020-09-28 타르서스 파마수티칼스, 아이엔씨. 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CN111265528A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
WO2022079496A1 (en) * 2020-10-13 2022-04-21 Menschlich Healthcare Opc Private Limited A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof
CN112294793B (zh) * 2020-10-21 2022-03-22 青岛海洋生物医药研究院股份有限公司 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用
WO2022130031A1 (en) * 2020-12-17 2022-06-23 Chander Mohan Negi A pharmaceutical composition of nitazoxanide and mefloquine and method thereof
CN118420621A (zh) * 2021-02-07 2024-08-02 南京知和医药科技有限公司 一种磺酰胺类多环化合物及其制备方法与用途
JP2025517707A (ja) * 2022-05-16 2025-06-10 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 蚊の防除の方法
WO2024168149A1 (en) * 2023-02-10 2024-08-15 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778566A (zh) * 2007-08-17 2010-07-14 英特威国际有限公司 异噁唑啉组合物及其作为抗寄生虫药的用途
WO2018081733A1 (en) * 2016-10-31 2018-05-03 The California Institute For Biomedical Research Methods and compositions for preventing vector-borne disease transmission

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
HRP20241712T1 (hr) * 2018-09-05 2025-02-14 Zoetis Services Llc Antiparazitske formulacije prihvatljivog okusa
CA3146043A1 (en) * 2019-07-22 2021-01-28 Intervet International B.V. Soft chewable veterinary dosage form

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778566A (zh) * 2007-08-17 2010-07-14 英特威国际有限公司 异噁唑啉组合物及其作为抗寄生虫药的用途
WO2018081733A1 (en) * 2016-10-31 2018-05-03 The California Institute For Biomedical Research Methods and compositions for preventing vector-borne disease transmission

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIELA CAVALLERI等: "A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe", 《PARASITES & VECTORS》, vol. 10, no. 531, 31 December 2017 (2017-12-31), pages 1 - 8 *
MARTIN MURPHY等: "Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against Ixodes ricinus ticks on dogs", 《PARASITES & VECTORS》, vol. 10, no. 541, 31 December 2017 (2017-12-31), pages 1 - 8 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118593485A (zh) * 2023-05-07 2024-09-06 M·法伯 异噁唑啉复合物及其组合物
CN118593485B (zh) * 2023-05-07 2025-04-22 M·法伯 异噁唑啉复合物及其组合物

Also Published As

Publication number Publication date
KR20220054241A (ko) 2022-05-02
BR112021019931A2 (pt) 2021-12-07
EP3946325A4 (en) 2022-12-21
AU2020251960A1 (en) 2021-11-11
CA3136042A1 (en) 2020-10-08
IL286914A (en) 2021-10-31
US20220160682A1 (en) 2022-05-26
EP3946325A1 (en) 2022-02-09
WO2020202111A1 (en) 2020-10-08
MX2021012188A (es) 2022-02-11
US20230218584A1 (en) 2023-07-13
JP2022527359A (ja) 2022-06-01

Similar Documents

Publication Publication Date Title
CN113993518A (zh) 用于媒介传播疾病和病毒性疾病治疗或预防的全身异噁唑啉驱虫剂
van den Enden Pharmacotherapy of helminth infection
ES2417157T3 (es) Composiciones de isoxazolina y su uso como antiparasitarios
Taman et al. Present-day anthelmintics and perspectives on future new targets
KR20100113500A (ko) 아레나바이러스 감염 치료용 항바이러스 약물
CN110167540A (zh) 用于预防媒介传播疾病的传播的方法和组合物
Gilles Selective primary health care: strategies for control of disease in the developing world. XVII. Hookworm infection and anemia
CA3222397A1 (en) Palatable veterinary compositions
JP2000515509A (ja) 脊椎動物、特に哺乳動物の寄生虫、特に外部寄生虫を駆除する方法と、この方法を実施するための組成物
CN101848710A (zh) 驱虫用组合物
CA2729730C (en) Use of nifurtimox for treating giardiasis
US7709534B2 (en) Method of treating strongyloides infections and medicaments therefor
US12502377B2 (en) Method of eradicating ticks that attach to humans using lotilaner formulations
JP2013542737A (ja) 昆虫侵入を阻害するための方法
RU2279874C9 (ru) Препарат для профилактики и лечения гельминтозов лошадей
CN1342081A (zh) 用于治疗由肉孢子虫、新孢子虫和弓形虫引起的疾病的三嗪酮化合物
CN102711730B (zh) 用于内部控制或治疗马类胃蝇幼虫的方法
US10226455B2 (en) Compositions and methods for drug sensitization of parasites
RU2287332C2 (ru) Препарат для профилактики и лечения гельминтозов животных
RU2823297C1 (ru) Ветеринарный фармацевтический продукт против эктопаразитов собак
US20250204555A1 (en) Feed and methods for controlling intestinal tract parasitic worm infections in mammals
RU2841949C1 (ru) Пероральная композиция фипронила с празиквантелом в качестве противопаразитарного средства для собак и кошек
RU2100022C1 (ru) Антигельминтное средство "азинокс плюс"
US11439638B1 (en) Drug and diagnostic combination system to identify and treat single-stranded RNA viruses including coronaviruses
WO2025136126A1 (es) Composición oral en forma de gel bioadhesivo a base de isoxazolina

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066895

Country of ref document: HK